A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
A phase 1/2 trial of FOLFIRI, Irinotecan, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Marengo Therapeutics, Inc., now recruiting.
Overview
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05592626 by Marengo Therapeutics, Inc., with 366 participants planned, started 2023-01-04 and due to reach its primary completion in 2027-09. Interventions recorded: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere). Conditions listed: Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Shares Irinotecan (and liposomal irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), Colorectal cancer.
- TrialA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Shares Docetaxel, Small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer.
- TrialPhase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Acti
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialSafety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Shares Docetaxel, Small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer.
- TrialSafety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che
Shares Docetaxel, Small-cell lung cancer, Non-small-cell lung cancer.